We investigated a number of parameters for host defense after the in vitro addition of the antifungal agents ketoconazole, amphotericin B (AMB), and amphotericin B methyl ester (AME). Similar assays were repeated before and after patients received the former two drugs. Viability by\trypan blue exclusion, adherence by nylon wool columns, chemotaxis by the under-agarose technique, phagocytosis and killing by chemiluminescence, colony counts, and acridine orange direct visualization were assayed. In striking contrast to AMB and AME, ketoconazole demonstrated no significant effect on neutrophils. Adherence in the presence of therapeutic plasma levels of AMB and AME was decreased (P s 0.005) at low drug concentrations, whereas at higher concentrations, adherence was increased (P < 0.001). The chemotactic responses of cells incubated with AMB and AME demonstrated marked suppression. Phagocytic capacity and killing were decreased (P s 0.005) with AMB as compared with control assays and assays performed in the presence of ketoconazole and AME. However, no differences were observed between two patients who received AMB and two others treated with ketoconazole.
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Many investigators have shown that not only do natural deficiencies and abnormalities alter the immunological responses, but such alterations can also be attributed to the toxicity of various antibiotics used in chemotherapy (7, 8, 14, 15) .
The major chemotherapeutic agent for systemic mycoses is amphotericin B (AMB), a polyene antibiotic. It is well documented that treatment with this antifungal drug is complicated by a variety of toxic effects to the patient (4, 17) . Amphotericin B methyl ester (AME) is a water-soluble derivative ofAMB first prepared by Mechlinski and Schaffner (16, 23) . It is significantly less toxic than its parent drug in mouse and dog models (9) (10) (11) AMB was purchased as a sterile, lyophilized, deoxycholate-stabilized, phosphate-buffered powder (Fungizone; E. R. Squibb & Sons, Princeton, N.J.), and AME aspartate was kindly supplied by Patrick A. Diassi, Squibb Institute for Medical Research, Princeton, N.J. These products were reconstituted in sterile distilled water, and dilutions were prepared fresh as mentioned above. Ketoconazole, AMB, and AME were added to either heparinized whole blood or washed cell suspensions and incubated for a minimum of 60 min before the various assays were performed. Control, or untreated, neutrophil suspensions were preincubated in buffer for the same duration of time. Since therapeutic plasma levels are 1 to 5, 0.2 to 3, and 15 to 30 ,tg/ml for ketoconazole, AMB, and AME, respectively, these concentrations were examined most carefully. Peak plasma concentrations for 50-, 100-, and 200-mg oral tablet doses of ketoconazole occurred after 1.8 to 2 h (mean values, 0.7, 1.28, and 3.4 ,ug/ml, respectively) (3). AMB therapy was begun at a dose of 0.25 or 0.5 mg/kg and was increased in 0.25-mg increments to a maximum dose of 1 mg/kg. At that time (5 to 6 days), peak AMB concentrations were obtained 1 h after completion of intravenous infusion (mean value, 1.21 Itg/ml) (6) . Blood from all patients was drawn during peak therapeutic drug levels, and no additional antifungal agents were added to the whole blood or neutrophil suspensions collected.
Cell viability. Whole blood and washed neutrophil suspensions were exposed for 3 h to various concentrations of each antifungal agent. Viability was assessed by the ability of the cells to exclude the vital dye trypan blue (21) . At 30-min intervals, samples of the whole blood or washed neutrophils were mixed with equal volumes of 0.4% trypan blue stain (GIBCO Laboratories, Grand Island, N.Y.). A total of 200 cells were counted microscopically, and the percent viability was determined. Neutrophil adherence. Adherence was measured with nylon fiber columns as previously described (13) . Briefly, 50 mg of nylon fiber was carefully packed into a Pasteur pipette to a measured length of 15 mm. A 1-ml amount of blood was dispensed into the column and allowed to filter through the nylon fiber by gravity.
The precolumn neutrophil count and differential were compared with the count of the effluent blood to ascertain the percentage of neutrophils adhering to the column. The percentage of adherent neutrophils was calculated as follows: adherence = 100% -[(neutrophils per milliliter in effluent sample/neutrophils per milliliter in original sample) x 100].
Chemotaxis. Neutrophils treated with ketoconazole, AMB, or AME in a serum-free system were assessed for their chemotactic responses to zymosanactivated autologous serum as previously described (18) . The agarose solution was dispensed into a sterile tissue culture dish (60 by 15 mm) and allowed to harden. Three wells, with a diameter of 2 mm and spaced 2.5 mm apart, were cut. Each plate contained six series of three wells. A 10-,ul amount of the cell suspension (108 neutrophils per ml), preincubated with the antifungal agents, was added to the middle wells in three of the six sets in the agarose plates. The remaining three middle wells were filled with 101, of control cell suspensions incubated in buffer. The six outer wells were all filled with 10 td of activated autologous serum, and the inner wells were filled with 10 ul of buffer. A 2-h incubation period was carried out at 37°C in a humidified atmosphere containing 5% CO2 in air. Plates were then fixed, and quantitation was determined by counts of migrated cells in a single plane (19) and expressed as a percentage of the control.
Chemiluminescence. Procedures for serum opsonization of zymosan particles and for the measurement of the chemiluminescence have been described in detail previously (1) . A beta-counting spectrometer was adjusted for out-of-coincidence. Dark-adapted polyethylene vials were filled with 4 ml of Gey balanced salt solution containing 106 neutrophils per ml and the appropriate concentration of the antifungal agent. The vials were counted in sequence to obtain background measurements. A 1-ml amount of opsonized zymosan particles was added to each vial at zero time, and each vial was counted for 15 s. All vials were counted sequentially until the peak chemiluminescence response could be determined. The peak chemiluminescence of neutrophils treated with the antifungal agents was expressed as a percentage of the peak chemiluminescence produced by control, untreated neutrophils from the same donor.
Preparation of bacteria (Staphylococcus aureus). 502A stock cultures, stored at -70°C in Trypticase soy broth (BBL Microbiology Systems, Cockeysville, Md.) with glycerol, were thawed and inoculated into 10 ml of Trypticase soy broth and incubated for 18 h at 37°C. The cultures were centrifuged and washed with Hanks balanced salt solution and adjusted to 1 x 108 to 5 x 108 bacteria per ml. They contained 10% autologous serum.
Phagocytic bactericidal assay. Phagocytosis and killing of bacteria were first measured using the bactericidal method (22) . Briefly, each 1-ml incubation mixture included 5 x 106 colony-forming units of bacteria. The suspensions contained 10% autologous serum with or without ketoconazole, AMB, or AME. The incubation period was performed at 37°C in plastic test tubes with horizontal rotation on a shaker at a rate of 120 rpm. Immediately after incubation, neutrophils were lysed by adding 9 ml of sterile distilled water to the reaction mixtures, serially diluting them in 0.9% NaCl, and spreading them on Trypticase soy agar (BBL Microbiology Systems) plates to quantitate VOL. 20, 1981 on June 18, 2017 by guest http://aac.asm.org/ Downloaded from viable bacteria. Also, a fluorochrome microassay with acridine orange as an indicator of viable cellular material, described previously (20) , was used to directly evaluate visual phagocytic and microbicidal functions of neutrophils exposed to the antifungal drugs. Blood was drawn in a syringe with no anticoagulant, and the appropriate concentration of ketoconazole, AMB, or AME was added and mixed. A leukocyte monolayer was prepared by dripping 0.2 ml of blood onto a sterile circular cover slip. All cover slips were incubated at 37°C in a humidified 5% CO2 incubator for 60 min. After incubation, the clot and serum were decanted and gently rinsed with Hanks balanced salt solution to remove nonadherent cells. A 0.1-ml amount of the standardized S. aureus 502A suspension was added to the monolayer which was placed on a flat rotator (10 rpm) at 37°C for 90 min. The cover slips were then carefully rinsed and stained with 0.14% acridine orange for 45 s. The coverslips were mounted on glass slides, monolayer side down, and the edges were sealed with clear nail polish. Examination was performed with an ultraviolet fluorescent microscope under a 10Ox oil immersion objective. For the quantitation of phagocytic capacity, the total number of dead (red) and live (green) intracellular bacteria in 100 leukocytes was counted on each of three cover slips. Killing and phagocytic capacity were determined by the following formulas: % killing = (number of red organisms/number of red and green organisms per 100 leukocytes) x 100, and phagocytic capacity = (number of red and green organisms/100 leukocytes).
Statistics. Statistical analyses were made with Student's t test.
RESULTS
Cell viability was assessed by trypan blue dye exclusion. In vitro exposure of whole blood and washed neutrophils to concentrations ranging from 0 to 10 Izg of ketoconazole per ml, 10 yg of AMB per ml, and 40 jg of AME per ml had no influence on cell death. Viability remained greater than 94% over a 3-h period.
Adherence of neutrophils in the presence of ketoconazole, AMB, and AME is summarized in Table 1 . The general trend of all three antifungal agents on the ability of neutrophils to adhere to nylon wool was demonstrated, with decreased to normal adherence at low drug concentrations and increased adherence at high drug concentrations. The attainable therapeutic plasma levels of ketoconazole and AME demonstrated normal adherence at low concentrations and increased (P s 0.01) adherence at higher concentrations.
AMB decreased (P < 0.001) adherence at 1 ,ig/ ml, but at 3 ,g/ml, it approached normal adherence.
Data from five chemotaxis experiments (Fig.  1 ) of ketoconazole-treated cells responded normally, but the effects of both AMB and AME on migrating neutrophils under agarose were 1 . Effect of ketoconazole, AMB, and AME on chemotaxis of normal human neutrophils preincubated for 60 min with therapeutically attainable concentrations of the drugs. All values are expressed as a percentage of the migration of cells incubated without the antifungal compounds (mean ± standard error of the mean). *, P = 0.001; *, P < 0.001; i**, P = 0.08. significantly depressed (P c 0.001) at therapeutically attainable plasma concentrations (1 to 3 and 10 to 20 jig/ml, respectively). The chemotactic responses to 3 ,zg of AMB per ml and to 20 ,ug of AME per ml, those peak levels most likely to be obtained in plasma during therapy, were both 15% (P < 0.001) of the control.
Neutrophil chemiluminescence during phagocytosis was measured at 15 min and 2 h after cells were incubated with the antifungal agents. Preincubating the cells for 15 min did not alter the response compared with untreated cells, but exposing neutrophils for longer periods of time revealed an inhibitory response with AMB and AME, but not with ketoconazole (Fig. 2) AME is slightly more suppressive than AMB at therapeutic plasma levels.
Both bactericidal assays are summarized in Table 2 . Bacterial destruction with ketoconazole-, AMB-, and AME-treated neutrophils was comparable to that with the untreated control cells by the colony count method. The fluorochrome microassay revealed that AMB-treated neutrophils had decreased phagocytic (P c< 0.005) and killing capacities (P = 0.01). Those treated with ketoconazole and AME were unchanged.
Four patients with mycotic infections were selected for in vivo antifungal studies, two treated with ketoconazole and two treated with AMB. Initial studies were performed before therapy. All patients were well into their course of therapy when blood was drawn, and the phlebotomy was performed to correspond to peak plas'ma levels of that particular drug.
Patient 1 (Table 3) , a 1-year-old white male with chronic mucocutaneous candidiasis, was treated with ketoconazole. With increasing doses, chemotaxis and killing capacity (chemiluminescence) increased, and the previously increased neutrophil adherence was unaffected. Patient 2, a 33-year-old white female with helminthosporium sinusitis, was treated with ketoconazole. Chemotaxis was unchanged, and sianilar to patient 1, neutrophil adherence was unaffected but remained increased. Patient 3, 76 years old with aspergillosis, was treated with AMB and 5-fluorocytosine. Chemotaxis increased killing of the Aspergillus species increased, and adherence remained elevated. Patient 4, 12 years old with aspergillosis, was treated with AMB and 5-fluorocytosine. Chemotaxis was unchanged, killing of the Aspergillus species increased, and adherence remained elevated.
DISCUSSION
Several lines of clinical and experimental data suggest that mechanisms of cell-mediated immunity are most critical in protecting the host from systemic mycoses (24) . However, disseminated fungal disease in patients with neutropenia (2) Recently, AME has been examined for clinical efficacy in the treatment of systemic mycoses. Experiences with patients appeared encouraging before a preliminary report of neuropsychiatric disturbances in patients who were receiving AME. Although these findings were supported by preliminary electroencephalographical and neuropathological data, they were mitigated by the presence of previous psychoses and fungal meningitis in some of the patients and by the administration of impure AME to a significant proportion of the affected individuals. Thus, although it is too soon to know whether this semisynthetic preparation will offer a therapeutic advantage or be too toxic for humans, manipulation of polyene antibiotic molecules still offers a means of improving the treatment of systemic mycoses. The newest oral broad-spectrum agent, ketoconazole, is active against many yeasts, dermatophytes, and dimorphous fungi (25) and has not as yet proven to be toxic in vivo. It was considered worthwhile, therefore, to assay the comparative effects on neutrophil function of the standard compound AMB, its semisynthetic analog AME, and its newest developed derivative, ketoconazole.
The present in vitro studies demonstrate no adverse immunotoxic effects of ketoconazole on neutrophil function, whereas AMB suppresses chemotactic responses, chemiluminescence, phagocytosis, and killing. At the same time, adherence was also decreased at low drug concentrations, whereas at higher concentrations, adherence was demonstrated to increase ( Table 1) . The mechanism for this selective effect of these antifungal drugs is intriguing. Evidence of the nature of membrane lesions resulting from polyene-sterol interactions supports the concept that the binding of polyenes to cell membranes induces changes in the physical properties of membranes (17) . Further studies are in progress to delineate this phenomenon. The production of neutrophils was the only other aspect of neutrophil function not evaluated. However, other studies have noted an increase of greater than twofold in the absolute neutrophil count during day 1 of therapy with AMB and then a return to base-line counts by day 2 (12 
